BioInfra Co., Ltd. (KOSDAQ:199730)
1,510.00
-21.00 (-1.37%)
At close: Sep 3, 2026
BioInfra Revenue
BioInfra had revenue of 8.50B KRW in the quarter ending June 30, 2026, with 39.74% growth. This brings the company's revenue in the last twelve months to 25.62B, up 4.69% year-over-year. In the year 2025, BioInfra had annual revenue of 23.15B, down -2.87%.
Revenue (ttm)
25.62B
Revenue Growth
+4.69%
P/S Ratio
0.28
Revenue / Employee
n/a
Employees
n/a
Market Cap
7.06B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 23.15B | -685.20M | -2.87% |
| Dec 31, 2024 | 23.83B | -6.30B | -20.90% |
| Dec 31, 2023 | 30.13B | -5.30B | -14.96% |
| Dec 31, 2022 | 35.43B | 4.87B | 15.94% |
| Dec 31, 2021 | 30.56B | 10.95B | 55.82% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2014 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| DreamCIS | 73.28B |
| HLB bioStep | 72.15B |
| C&R Research | 63.55B |
| DT&CRO CO. | 49.00B |
| Kolmar BioTech | 40.30B |
| P&K Skin Research Center | 23.67B |
| Penetrium Bioscience | 9.74B |
| Curachem | 6.02B |